Cytokinetics Incorporated

Financials

Overview Estratto Conto Statistics Dividends

Total assets 1.44 B1.4 B1.26 B1.23 B1.44 B1.42 B Total liabilities 1.45 B1.54 B1.53 B1.59 B1.96 B2.08 B Total equity 13.91 M135.37 M266.41 M368.72 M521.12 M659.63 M Total liabilities & shareholders' equities 1.44 B1.4 B1.26 B1.23 B1.44 B1.42 B Total debt —————— Net debt ——————

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

CYTK

Financials

Cytokinetics Incorporated

Notizie

BofA alza il target su Cytokinetics a $67 per Myqorzo

BofA raises Cytokinetics stock price target to $67 on Myqorzo

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans

Needham alza il target su Cytokinetics a $85 per le prospettive dello studio

Needham raises Cytokinetics stock price target to $85 on trial outlook

Citizens alza il target su Cytokinetics a $96 per progressi nel lancio

Citizens raises Cytokinetics stock price target to $96 on launch progress

Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo